Swiss National Bank raised its position in Pfizer Inc. (NYSE:PFE) by 8.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 18,298,389 shares of the biopharmaceutical company’s stock after buying an additional 1,412,800 shares during the period. Pfizer makes up about 1.0% of Swiss National Bank’s portfolio, making the stock its 11th largest position. Swiss National Bank owned approximately 0.30% of Pfizer worth $644,286,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Stelac Advisory Services LLC acquired a new stake in Pfizer during the second quarter worth about $110,000. Catamount Wealth Management raised its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the last quarter. Commonwealth Financial Services LLC raised its stake in Pfizer by 5.5% in the second quarter. Commonwealth Financial Services LLC now owns 4,023 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 210 shares during the last quarter. Stuart Chaussee & Associates Inc. raised its stake in Pfizer by 64.3% in the second quarter. Stuart Chaussee & Associates Inc. now owns 5,430 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,125 shares during the last quarter. Finally, Jag Capital Management LLC acquired a new stake in Pfizer during the second quarter worth about $202,000. 69.65% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer Inc. (NYSE:PFE) traded up 0.56% during trading on Tuesday, hitting $33.83. 15,491,512 shares of the stock were exchanged. Pfizer Inc. has a one year low of $28.25 and a one year high of $37.39. The stock has a market cap of $205.20 billion, a PE ratio of 29.99 and a beta of 0.87. The stock’s 50 day moving average price is $34.63 and its 200 day moving average price is $34.00.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the firm posted $0.56 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.55%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is 95.24%.
PFE has been the subject of a number of analyst reports. Vetr raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price objective for the company in a report on Tuesday, August 2nd. Sanford C. Bernstein reissued an “outperform” rating on shares of Pfizer in a report on Monday. Piper Jaffray Cos. reissued an “overweight” rating and issued a $54.00 price objective on shares of Pfizer in a report on Monday, June 27th. TheStreet raised shares of Pfizer from a “hold” rating to a “strong-buy” rating in a report on Friday, June 3rd. Finally, BMO Capital Markets reissued a “buy” rating and issued a $40.00 price objective on shares of Pfizer in a report on Thursday, July 21st. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $38.78.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.